Alfacalcidol
Uses of Alfacalcidol
Alfacalcidol is commonly used to treat Hypocalcaemia, Hypoparathyroidism, Hypophophataemia, Renal osteodystrophy and Rickets/osteomalacia
How Alfacalcidol Works
Alexitol sodium acts as an antacid which buffers and neutralizes the hyperacidity of the stomach. This is achieved by the interaction of the excess proton (hydrogen ion) with the Alexitol sodium compound that reduced the excess of hydrogen ions in the stomach thus relieving the symptoms of indigestion, heartburn and peptic ulcer disease.
Side Effects of Alfacalcidol
Constipation, Intestinal obstruction (when overdosage), Dizzy, Headache, Stomach discomfort, Tiredness
Warnings
Kidney Use With Care
Alfacalcidol is regularly used in patients with renal impairment. Caution should be taken to avoid hyperphosphataemia either by taking together with phosphate binders or monitoring closely level of phosphate in the blood.
Alcohol Safe
Consumption of alcohol with Alfacalcidol is thought to be safe and does not affect the absorption of Alfacalcidol based on the clinical data.
Pregnancy Not Safe
Animal studies have shown reproductive toxicity in higher dose while there is only limited data regarding the safety profile of Alfacalcidol during human pregnancy. It is therefore should be avoided to be used during pregnancy or use with caution by doctor's advice.
Driving Not advisable
It is not advisable to consume Alfacalcidol before driving if side effects such as dizziness or headache developed.
Liver Safe If Prescribed
Alfacalcidol is noted to be safe and may only cause slight increase in liver enzymes level in people with hepatic impairment.
Lactation Limited Data
It is not fully known how much the active calcitrol will be in the breastmilk. The presence of this active metabolites may disturb the normal calcium metabolism of an infant. Hence, it is advisable to closely monitor the infant's health following the mother's intake of Alfacalcidol.
Frequently Asked Questions
Written by Dr Sri Viknarajan, MD (Universiti Hasanuddin, Indonesia)
Reviewed by Dr Nur Syuhada binti Zulkifli, MD, Universiti Kebangsaan Malaysia (UKM).
